ALX Oncology Holdings Inc (ALXO)
1.515
+0.02
(+1.68%)
USD |
NASDAQ |
Nov 05, 16:00
1.53
+0.02
(+0.99%)
After-Hours: 19:07
ALX Oncology Holdings Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2020 | 0.0622 |
| March 31, 2020 | 0.0558 |
| Date | Value |
|---|---|
| December 31, 2019 | -19.64 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-19.64
Minimum
Dec 2019
0.0622
Maximum
Jun 2020
-6.508
Average
0.0558
Median
Mar 2020
Debt to Equity Ratio Benchmarks
| Biomarin Pharmaceutical Inc | 0.1098 |
| Neurocrine Biosciences Inc | 0.00 |
| Eton Pharmaceuticals Inc | 0.346 |
| Verve Therapeutics Inc | 0.00 |
| Immuneering Corp | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 214.62M |
| Total Liabilities (Quarterly) | 55.30M |
| Shareholders Equity (Quarterly) | 159.32M |